Study guide

5.1 Osteosarcoma and Ewing Sarcoma

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

5.1 Osteosarcoma and Ewing Sarcoma

Key Takeaways Explain This Topic AI

Osteosarcoma arises in the metaphysis of long bones—distal femur, proximal tibia, proximal humerus—in adolescents and presents with pain, a mass, and sometimes pathologic fracture; lungs are the most common metastatic site.

Imaging cues for osteosarcoma include sunburst periosteal reaction, Codman triangle, and skip metastases; MAP-like chemotherapy (high-dose methotrexate with leucovorin rescue, doxorubicin, cisplatin) plus limb-salvage or amputation is the local-control pair.

Delayed methotrexate clearance is managed with hydration, urine alkalinization, timed leucovorin, and glucarpidase as the concept for toxic levels; doxorubicin is cardiotoxic and cisplatin is ototoxic and nephrotoxic.

Ewing sarcoma involves diaphysis, flat bones, or soft tissue, often in a slightly younger child, with onion-skin periosteal reaction, systemic symptoms that mimic osteomyelitis, and t(11;22) EWSR1-FLI1 as the teaching translocation.

Ewing uses VDC/IE-style cycles (vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide) plus surgery and/or radiation; give mesna for hemorrhagic cystitis, watch ifosfamide neurotoxicity (methylene blue as a supportive concept), and treat fever-neutropenia as an emergency.

Last updated: August 2026

A 14-year-old soccer player reports six weeks of night pain just above the knee. Urgent care called the joint radiograph normal. A dedicated femur film shows a distal femoral metaphyseal lesion with a sunburst periosteal reaction and a Codman triangle. That presentation is osteosarcoma until an orthopedic oncologist biopsies it. CPHON items on bone sarcomas ask you to separate osteosarcoma from Ewing sarcoma by age, bone site, imaging, genetics, and local-control strategy—and to keep a child alive through high-dose methotrexate, anthracyclines, ifosfamide, and fever-neutropenia.

Osteosarcoma: metaphysis, adolescents, lungs

Osteosarcoma is the most common primary malignant bone tumor of childhood and adolescence. Incidence peaks with the adolescent growth spurt. Classic sites are the metaphysis of long bones : distal femur, proximal tibia, and proximal humerus. Around-the-knee locations dominate. The history is progressive pain, a firm mass, limp, night pain that does not match a sprain timeline, and sometimes a pathologic fracture after modest trauma. Do not close the workup because a sports-medicine film of the joint missed the metaphysis.

Plain films classically show a mixed lytic-sclerotic lesion, sunburst periosteal reaction, and Codman triangle . Magnetic resonance imaging of the entire involved bone maps skip metastases —discontinuous tumor in the same bone or across the adjacent joint—that change surgical margins. Chest computed tomography hunts the most common distant site: lung . Bone scan or positron-emission tomography looks for skip lesions and skeletal metastases. Alkaline phosphatase and lactate dehydrogenase may be elevated; they support suspicion but do not replace biopsy. Biopsy belongs to the treating orthopedic oncology team so the tract can sit inside the future resection.

MAP-like chemotherapy, limb salvage, and the implant

Contemporary pediatric osteosarcoma uses neoadjuvant multi-agent chemotherapy, surgical local control, then adjuvant chemotherapy informed by histologic necrosis. The MAP-like backbone is high-dose methotrexate with leucovorin rescue , doxorubicin , and cisplatin . Osteosarcoma is relatively radioresistant. Radiation is not first-line local control for an extremity lesion that can be resected with a functional reconstruction.

Limb-salvage with wide resection and reconstruction—endoprosthesis, allograft, or rotationplasty—is preferred when an oncologically adequate, usable limb can be preserved. Amputation remains correct when the neurovascular bundle cannot be spared, when infection or pathologic fracture destroys reconstruction, or when the team and family judge function better with an external prosthesis. Rotationplasty is not a consolation prize; for a growing athlete it can provide durable below-knee–style function.

Endoprosthesis teaching is lifelong. No contact sports that torque the implant. Fever plus a reconstructed joint is infection until proven otherwise. Growing children need planned revisions for limb-length discrepancy and loosening. Physical therapy is part of oncologic care, not an afterthought. A warm, swollen salvage knee at home is an emergency visit, not a wait-until-clinic-Monday plan.

Toxicities the CPHON nurse owns on MAP

High-dose methotrexate is a timed rescue, not a once-daily home tablet. Hydrate. Alkalinize urine, typically targeting pH of 7 or higher. Give leucovorin on the protocol clock. Third-space fluid—pleural effusion, ascites, obstructed bowel—delays clearance. Hold interacting drugs the protocol names, commonly including nonsteroidal anti-inflammatory drugs and trimethoprim-sulfamethoxazole around the methotrexate window. Serial serum methotrexate levels drive how long rescue continues. Glucarpidase is the concept used when delayed clearance plus toxic methotrexate levels threaten the kidneys and mucosa: a carboxypeptidase that cleaves methotrexate, given with expert pharmacy support, not as a casual extra leucovorin dose.

Doxorubicin drives cumulative cardiotoxicity. Track lifetime milligrams per square meter, obtain protocol echocardiograms, and teach families that activity tolerance and future heart-failure risk are part of survivorship. Cisplatin drives ototoxicity and nephrotoxicity . Serial audiograms belong on the roadmap; classroom hearing support is a nursing referral, not a surprise at parent-teacher night. Hydrate around cisplatin, replete magnesium, watch creatinine, and avoid stacking nephrotoxins. Antiemetic premedication is a safety intervention; MAP nausea is not optional discomfort.

Ewing sarcoma: diaphysis, flat bone, soft tissue, and the infection mimic

Ewing sarcoma is a small-round-blue-cell tumor of bone or extraosseous soft tissue. Peak age is often slightly younger than classic osteosarcoma and includes school-age children, though teenagers are common. Typical sites are the diaphysis of long bones, flat bones (pelvis, scapula, ribs, vertebrae), chest wall, and pure soft-tissue masses. Fever, weight loss, malaise, and a high erythrocyte sedimentation rate or C-reactive protein make Ewing look like osteomyelitis . Do not treat a lytic diaphyseal lesion as culture-negative chronic infection for weeks without a planned biopsy; delayed diagnosis delays systemic therapy.

Imaging classically shows onion-skin (lamellated) periosteal reaction and a large soft-tissue mass. Magnetic resonance imaging defines extraosseous extent. Staging includes chest imaging, skeletal or positron-emission tomography survey, and bilateral bone-marrow evaluation on many protocols, because marrow joins lung and bone as a classic metastatic site. The teaching genetic point is t(11;22) producing EWSR1-FLI1 . Other EWSR1 partners exist. The CPHON distinction is that Ewing is a translocation-defined sarcoma, not osteosarcoma in a younger child.

VDC/IE-style cycles, mesna, methylene blue, fever

Treat Ewing as systemic disease from day one. Interval-compressed VDC/IE-style cycles use vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide , plus local control with surgery, radiation, or both. Unlike osteosarcoma, Ewing is radiosensitive . Unresectable pelvic or vertebral disease often needs radiation. Surgery is chosen when complete resection with acceptable function is realistic.

Mesna accompanies ifosfamide and higher-dose cyclophosphamide to bind acrolein and prevent hemorrhagic cystitis . Nursing means timed mesna, vigorous hydration, and heme-positive urine as an emergency signal—not a wait for the next voiding diary. Ifosfamide neurotoxicity —somnolence, confusion, hallucinations, seizures—is a supportive-care concept. Methylene blue is used in selected cases with the oncology team after hypoglycemia and other metabolic causes are considered. Ifosfamide also wastes renal tubular electrolytes; check phosphate, potassium, bicarbonate, and urine protein.

Vincristine constipation and neuropathy need a bowel regimen before the next dose, not after obstruction. Anthracycline echo rules still apply. Fever during neutropenia after these intensive cycles is an emergency: cultures, prompt broad-spectrum antibiotics, and no instruction to wait until morning clinic. Families hear that looking well at 18:00 does not cancel 38.3°C at 02:00.

A 9-year-old with fever, a painful tibial shaft, and onion-skin periosteum is not chronic osteomyelitis until Ewing is excluded. A 15-year-old with a distal femoral metaphyseal mass and pulmonary nodules is osteosarcoma until proven otherwise. Keep the maps separate so MAP hydration and VDC/IE mesna are not swapped at the chairside.

  • Feature Osteosarcoma Ewing sarcoma
  • Typical age Adolescent growth spurt Often younger school-age to adolescent

Bone / tissue site Metaphysis (distal femur, proximal tibia, proximal humerus) Diaphysis, pelvis and other flat bones, extraosseous soft tissue

Imaging cue Sunburst, Codman triangle, skip metastases Onion-skin periosteal reaction, large soft-tissue mass

Genetics teaching point Complex osteoid-producing sarcoma (not a single fusion for CPHON scoring) t(11;22) EWSR1-FLI1

Distant metastases Lungs first Lungs, bone, bone marrow

Chemo example MAP-like: high-dose methotrexate, doxorubicin, cisplatin VDC/IE-style: vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide

  • Local control Surgery (limb-salvage vs amputation); radiation not primary Surgery and/or radiation
  • Common mimic Growing pains, sports injury Osteomyelitis

Loading diagram... Osteosarcoma versus Ewing sarcoma treatment maps